Ritu Salani

1 week ago | onclive.com | Ritu Salani |Kathleen Moore

Author(s):,Panelists discuss how evolving insights into HER2 expression—drawn from parallels with breast cancer—highlight the need for standardized HER2 testing in gynecologic oncology, as emerging data on HER2-low status and variability in current testing approaches underscore both the therapeutic potential of antibody-drug conjugates (ADCs) and the challenges of implementing precision medicine in this setting.

1 week ago | onclive.com | Ritu Salani |Kathleen Moore

Author(s):,Panelists discuss how antibody-drug conjugates (ADCs) and molecular testing are reshaping treatment strategies in ovarian and endometrial cancers by enabling more personalized, targeted care, while addressing practical challenges such as tissue limitations, tumor heterogeneity, and the evolving role of liquid biopsy in optimizing diagnostic accuracy.

2 months ago | onclive.com | Ritu Salani

CommentaryVideoMarch 11, 2025Author(s):Fact checked by:Ritu Salani, MD, MBA, discusses considerations in clinical trial design and the evolving role of HER2-targeted ADCs in gynecologic malignancies. "We need to think outside the box a little bit.

Feb 12, 2025 | curetoday.com | Ritu Salani

Dr. Ritu Salani, a board-certified gynecologic oncologist and the Director of Gynecologic Oncology at the University of California, Los Angeles (UCLA), UCLA Health, sat down for an interview with CURE on the topic of cervical cancer.

Jan 28, 2025 | curetoday.com | Ritu Salani

During January, Cervical Cancer Awareness Month, it is important to bring awareness to the disease’s treatment landscape. A vital aspect of cervical care for patients to be aware of is side effects, and the mitigation of these side effects. In an interview with CURE®, Dr. Ritu Salani shared her advice for patients undergoing advanced treatment options for their cancer — such as immunotherapy or other targeted options — and emphasized the importance of always speaking with your health care team.